Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-cash Items (2018 - 2024)

Serina Therapeutics (SER) has disclosed Non-cash Items for 7 consecutive years, with $13000.0 as the latest value for Q2 2024.

  • Quarterly Non-cash Items fell 99.57% to $13000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $13000.0 through Jun 2024, down 99.57% year-over-year, with the annual reading at $80000.0 for FY2023, 97.25% down from the prior year.
  • Non-cash Items hit $13000.0 in Q2 2024 for Serina Therapeutics, up from $4000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $3.1 million in Q3 2023 to a low of $4000.0 in Q1 2024.
  • Historically, Non-cash Items has averaged $1.7 million across 5 years, with a median of $2.0 million in 2020.
  • Biggest five-year swings in Non-cash Items: soared 2622.43% in 2022 and later plummeted 99.87% in 2024.
  • Year by year, Non-cash Items stood at $239000.0 in 2020, then tumbled by 55.23% to $107000.0 in 2021, then skyrocketed by 2622.43% to $2.9 million in 2022, then crashed by 97.25% to $80000.0 in 2023, then crashed by 83.75% to $13000.0 in 2024.
  • Business Quant data shows Non-cash Items for SER at $13000.0 in Q2 2024, $4000.0 in Q1 2024, and $80000.0 in Q4 2023.